We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections (COMPAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00939185
Recruitment Status : Completed
First Posted : July 14, 2009
Results First Posted : March 18, 2010
Last Update Posted : March 30, 2010
Information provided by:

Brief Summary:
The objective of this study was to obtain data on the safety, tolerability and compliance with Zithromax in children with bacterial infections of the upper and lower respiratory tract.

Condition or disease Intervention/treatment Phase
Respiratory Tract Infections Drug: Azithromycin Phase 4

Detailed Description:
Patients were recruited from the outpatient departments of the participating sites/hospitals/clinics.

Study Type : Observational
Actual Enrollment : 400 participants
Time Perspective: Prospective
Official Title: Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections
Study Start Date : April 2007
Primary Completion Date : January 2009
Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Azithromycin group Drug: Azithromycin
Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
Other Name: Zithromax

Primary Outcome Measures :
  1. Number of Patients With Adverse Events (AEs) [ Time Frame: 3 to 7 days after receiving treatment ]
    All observed or volunteered AEs regardless of suspected causal relationship to the investigational product(s) were reported.

Secondary Outcome Measures :
  1. Number of Subjects Who Withdrew From the Study [ Time Frame: 3 to 7 days after receiving treatment ]
  2. Compliance [ Time Frame: 3 to 7 days after receiving treatment ]
    Compliance was assessed by the following questions: Question 1: "Were the pediatrician's instructions during the treatment phase followed (i.e. dose, frequency and number of days)?"; Question 2: "Was it easy to understand your pediatrician's instructions regarding treatment?"; and Question 3: "Was the administration of this drug easier than any other previously used drug?" Patients could answer either "yes", "no", or "Not applicable (NA)".

  3. Time Reported for a Patient Being Consulted and Diagnosed From the Moment He/She Entered the Hospital [ Time Frame: Day 1 ]
    Time of exam completion minus the start time of the examination.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   1 Year to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
ZITHROMAX® administration will be considered in children / adolescents from the first year of life up to 14 years old with the following diagnoses: Acute otitis media, Sinusitis, Pharyngitis/tonsillitis, Pneumonia, Bronchitis.

Inclusion Criteria:

  • Patients with respiratory tract infections that received azithromycin according to the approved SPC as this was a non-interventional study.

Exclusion Criteria:

  • According to the approved Summary of Product Characteristics (SPC) for Azithromycin as this was a non interventional study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00939185

Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00939185     History of Changes
Other Study ID Numbers: A0661182
First Posted: July 14, 2009    Key Record Dates
Results First Posted: March 18, 2010
Last Update Posted: March 30, 2010
Last Verified: March 2010

Keywords provided by Pfizer:
Compliance and Safety Study in Children with Upper and Lower Respiratory Tract Infections

Additional relevant MeSH terms:
Communicable Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Anti-Bacterial Agents
Anti-Infective Agents